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Summary The FAMMM syndrome consists of the familial occurrence of cutaneous malignant melanoma and
atypical nevi (dysplastic nevi), and is inherited as an autosomal dominant trait. Conflicting results have been
reported on the question of whether the syndrome includes increased susceptibility to non-melanoma cancers.
We have studied cancer of all anatomic sites and histologies in nine FAMMM families which were ascertained
in a pigmented lesions clinic in the Netherlands. We evaluated two hypotheses: that the number of systemic
cancers observed in the families was excessive, compared to expected incidence, based on Dutch incidence
data, and that there was variation (or heterogeneity) among families in the frequency of systemic cancer. A
significant excess of systemic cancer (especially digestive tract cancer) was observed. Significant heterogeneity
was also found among the families; three of the nine families had marked excess in numbers of systemic
cancers, and the remaining families had normal numbers of cancers among the known FAMMM gene carriers
and their first degree relatives. Thus, we provide evidence of increased susceptibility to systemic cancer
occurring in conjunction with the FAMMM syndrome in a subset of this resource.
The familial atypical multiple mole melanoma (FAMMM)
syndrome (D-2 familial type of the dysplastic nevus syn-
drome (Kraemer, 1983)) is characterised by the familial
occurrence of malignant melanoma of the skin in combina-
tion with multiple atypical nevi (dysplastic nevi). It appears
to be transmitted as a dominant, autosomal gene, with
variable expressivity within families, including nonpene-
trance, of the cutaneous phenotype.
In one of the original reports of FAMMM pedigrees
(Lynch et al., 1981a), a possible association of the syndrome
with primary non-melanoma neoplasms was described. How-
ever, this association is controversial and negative findings
have been reported (Greene et al., 1987). According to the
authors of these two reports, differing methods of family
ascertainment may account for this discrepancy. The finding
of increased incidence of systemic cancer has been attributed
to uncorrectable bias in favour of families prone to cancer at
several sites. The study reporting no increased systemic
cancer incidence has been faulted for failing to consider
heterogeneity among families in the FAMMM phenotype,
i.e. for pooling results from many FAMMM families rather
than focusing on the supposed subset of families in which the
susceptibility to systemic cancer was elevated, and for includ-
ing second degree relatives.
We conducted research to resolve this problem and now
provide evidence of an increase in extracutaneous cancer in a
subset of FAMMM families.
Materials and methods
Clinical and genetic studies were performed in all kindreds in
which at least three individuals with melanoma occurred.
These kindreds were ascertained by interviewing all
melanoma patients coming to the surgical oncology depart-
ment of the University Medical Center in Leiden, The
Netherlands, about the presence of melanoma in their
relatives. If there was a positive response, family studies were
begun. These family studies involved interviews of family
members and examinations for cutaneous signs of the
FAMMM by a dermatologist (W.B.), and continued
monitoring of these families. Cutaneous signs of the
FAMMM were defined as pathology-verified malignant
melanoma (cutaneous malignant melanoma in all cases), his-
tologically verified dysplastic nevi, or clinically dysplastic
nevi. Nevi were said to be clinically dysplastic when they
were large (>5 mm), predominately macular, irregular in
outline, and variegated in colour. All clinical judgements
were made by an experienced dermatologist (W.B.); most
cases were found to have multiple, clearly dysplastic nevi but
these were not excised for histological study because they
were not suggestive of frank melanoma. Methods used in
these studies have been described in detail elsewhere, as have
the clinical and pathological findings in some of the families
(Bergman et al., 1986, 1988; Vasen et al., 1989).
In these family studies, information was solicited about the
occurrences of non-melanoma cancers in family members.
When cancer diagnoses were reported, we attempted to verify
the diagnoses through review of pathology reports and/or
medical records from the diagnosing hospital. In some cases,
these were not available, and verification was sought from
the family physician and/or the death certificate.
Selection offamilies and individualsfor study
We included in this investigation all families under study at
Leiden which were well-documented FAMMM kindreds.
There were 10 such families in the resource. We selected the
members of these families most likely to be carrying the
FAMMM gene, and those who were most likely to be infor-
mative with regard to systemic cancer. We excluded all
married-in family members and all blood relatives who were
not known to have a first degree relative with cutaneous
signs of the FAMMM. Obligate gene carriers, blood relatives
not known to have cutaneous signs of the FAMMM but
known to have descendents with the FAMMM, were
included. Thus, FAMMM gene carriers and family members
at 50% risk of being a gene carrier were included. Then, we
excluded all persons born after 1950, since they were unlikely
to have developed systemic cancer, and all those born before
1880, since cancer diagnostic information in such cases was
not likely to be verifiable. After identifying these high risk
relatives, we excluded one of the original 10 families (family
3), because it included fewer than 10 high-risk relatives. In
the nine remaining families, a total of 200 cases met the
criteria for inclusion.
Statistical analysis
Comparison of actual cancer incidence to expected
incidence Age at death or present age was calculated for
each of the 200 family members included in the study. These
ages were grouped into 5-year intervals for analysis, and the
number of males and females in each age group was deter-
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mined. Incidence data was obtained from tables of first
admissions due to malignant neoplasms by age, sex and site
per 100,000 of the Dutch population, 1984 and 1985 (de
Campos Cordozo et al., 1987). These data were used to
calculate cancer risk up to the end of each 5-year period,
using the density methods for calculating risk as described by
Kleinbaum et al. (1982). These risks were multiplied by the
number of persons in that age category, and summed over all
sexes and ages, to compute the expected number of of cases
of cancer. This procedure was used to calculate expected
numbers of non-skin cancers, all digestive system cancers (as
defined by de Campos Cardozo (1987), including mouth,
pharynx, stomach, small bowel, colorectal, liver, gallbladder,
pancreatic, and other cancers of the digestive tract), panc-
reatic cancers, and digestive tract cancers other than panc-
reatic. Expected cancer rates for other specific sites and organ
systems were also calculated.
Actual cases of cancer other than skin cancer among the
200 cases were counted. Most diagnoses (65%) were verified
by actual pathology report and/or by medical records from
the hospital at which the diagnoses occurred. In 9% of the
cases, such documentation was not available, but a diagnosis
was recorded by the family physician, or on the death
certificate. Finally, in 26% of the cases, no documentation of
family-reported diagnoses was available. All cases where the
primary site was unknown, but melanoma could not be
excluded as a possible diagnosis, were excluded from the list.
We performed two sets of statistical analyses, one in which
all these cancer diagnoses were counted, and one in which
unverified family reports of diagnoses were excluded.
Statistical tests of the hypothesis that the observed number
of cancers differed from the expected number were performed
using a test attributed to Byar and described by Breslow and
Day (1987). Standardised incidence ratios (observed/expected
numbers of cancers) were also calculated, as an approxima-
tion of the relative risk. If significantly increased numbers of
cancers were observed, the hypothesis that the relative risk
was larger in the group of known gene carriers (affected and
obligate gene carriers) than among their first degree relatives
(who were at 50% risk of carrying the gene) was tested using
the procedure described by Breslow and Day (1987) for
comparing standardised mortality ratios between two
exposure groups.
Evaluation of heterogeneity among families The statistical
procedure used to test whether there was significant
heterogeneity among the nine families in the frequency of
occurrence of systemic cancer is called the 'permutation test'.
An early application related to breast cancer probands and
the incidence of cancer in their relatives (Lynch et al., 1981b).
In brief, all eligible high risk members of the nine families
were pooled, and stratified by year of birth (YOB) (before vs
after 1930), sex, and age (at cancer diagnosis (if any), at
death, or at present). The relative frequency of ext-
racutaneous cancer diagnosis in each stratum was calculated.
For each case in each family, the cancer probability was
taken to be equal to the relative frequency (p) of cancer in
his stratum, and the variance of this was taken to be p
(1-p). These variables were summed up for each family, to
arrive at the expected incidence of cancer in the family and
the variance. Then, a z score was calculated for each family,
as follows: z = (observed -expected)/(variance)'/2.
The goal of the procedure was to determine whether the
dispersion of the z scores was greater than would be expected
if cancer risk was homogeneous among the families, so the
variance of the z scores of the nine families was calculated,
and the probability of finding a variance of that size (or
larger) was determined, under the null hypothesis of
homogeneity.
Permutations were used to empirically determine the dist-
ribution of z score variances under the null hypothesis of
homogeneity. Each permutation involved reconstructing each
of the families at random from the pooled set of relatives
(within sex, age and YOB restrictions), recalculating z, and
calculating the variance of z among families. Ninety-nine
such permutations were performed. Whenever the variance of
the actual z score was larger than 95% of the variances
found in the permutations, the hypothesis of homogeneity
was rejected in favour of the alternative hypothesis that
significant heterogeneity existed.
When the hypothesis of homogeneity was rejected, the
distribution of actual z scores in the families was used to
identify families with extremely high or low frequencies of
cancer diagnosis. These z scores were adjusted for the size
and structure of the family as a result of the computation
described above.
Results
Forty-three extracutaneous cancers were reported among the
200 high risk family members studied. Table I gives the
expected numbers of cancer diagnoses derived from the
Dutch incidence data, both for all extracutaneous sites and
for certain subsets of cancers which were found to occur at
high frequency. Significantly higher than expected frequencies
of digestive system cancer, especially pancreatic cancer, were
found in the nine families. These excesses were highly
significant, even when only verified cancers were included.
There was some evidence of an excess of digestive system
cancers even when pancreatic cancers were excluded, but
when unverified cancers were excluded, this finding fell short
of statistical significance (P<0.06). Other cancer subsets
tested (e.g. breast cancer, respiratory system cancer) showed
no excess.
The permutation test was performed several times: on all
reported extracutaneous cancers, on all verified extra-
cutaneous cancers, on all reported digestive system cancers,
and on all verified digestive system cancers. No other sub-
categories of cancer were reported sufficiently frequently to
warrant analysis through this method. The results of the
analyses involving all reported cancers are shown in Figure 1;
results of all other analyses are similar. The variance of
observed z scores was, in all analyses, significantly larger
than the variances of z scores calculated in the permutations.
In the analyses of all reported cancer, whether restricted to
verified cases or not, all variances generated by permutations
were less than the observed variance; in the case of all
digestive system cancers, 98% of permutations produced
variances smaller than the observed variance, and in the case
of verified digestive system cancers, 99% of the permutations
produced variances smaller than the observed variance.
Reruns of the permutation analysis with 1,000 permutations
Table I Comparison of observed frequency of cancer with expected
frequency
Observed
Cancer Reported Verified Expected OIE
200 individuals in nine families
All systemic sites 43** 32 22.0
All GI sites 21** 18** 5.4 3.3
Pancreatic carcinoma 9** 8** 0.6 13.4
All GI except pancreas 12* 10 4.8
All sites except GI 22 14 17.6
81 individuals in three families
All systemic sites 32** 27** 9.7 2.8
All GI sites 18** 17** 2.5 6.7
Pancreatic carcinoma 9** 8** 0.3 28.2
All GI except pancreas 9* 9* 2.3 3.9
All sites except GI 14 10 7.7
119 individuals in 6 families
All systemic sites 11 5 12.2
All GI sites 3 1 2.9
Pancreatic carcinoma 0 0 0.3
All GI except pancreas 3 1 2.6
All sites except GI 8 4 9.9
*P<0.01 (ifP<0.01 and there was an excess ofverified cancers or a
deficit ofreported cancers, the ratio O/E = observed/expected is given).
**P<0.001.934 W. BERGMAN et al.
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Figure 1 Distribution of z-score variances calculated in 99 per-
mutations of family data on all reported extracutaneous cancers.
The probability of obtaining the observed z-score variance (3.35),
given the hypothesis of homogeneity among families, is less than
0.01.
confirmed these findings, which indicate that the nine families
are heterogeneous with regard to the frequency of ext-
racutaneous cancer.
Three of the families (families 106, 2 and 4, which are
shown in Figure 2) had z scores of approximately + 2,
indicating a high frequency of cancer diagnosis compared to
other families in the set. The cancers reported in these three
families are detailed in Table II. The remaining six families
had negative z scores. From the overall analysis of observed
vs. expected numbers based on Dutch incidence figures, it
was clear that some of this heterogeneity might be due to
exceptionally high systemic cancer incidence in families 2, 4,
and 106; but it was not clear whether the other families had
unusual cancer frequency, such as very low frequency.
Therefore, expected and actual numbers of cancers in the
three families with the high z scores and in the six families
with the low z scores was calculated, following the same
method previously used for all nine families. These results are
given in Table I. The three high z score families have clearly
excessive numbers of digestive system cancers, especially pan-
creatic cancers, but also digestive system cancers other than
pancreas. The six low z score families have no excess of
cancer as a whole, or of any subset of cancer; nor do they
have a significantly lower frequency of cancer than expected.
Given the high incidence of systemic cancer in families 2,
4, and 106, the question of the association between systemic
cancer and FAMMM status arose. As the pedigrees in Figure
2 show, three cancer diagnoses have been reported in appar-
ently low risk family members. The two pancreatic cancers
reported in family 4 (individuals 11-1 and 11-3) occurred in a
branch of the family which has not, to our knowledge, been
examined for FAMMM characteristics. A laryngeal cancer in
family 2 (individual III-28) occurred in a patient who has
been examined, and whose children have been examined, and
no signs of the FAMMM were found. No other systemic
cancers have been reported in lower risk family members. We
compared the frequency of cancer among the 40 known gene
carriers (affected and obligate gene carriers) to that among
the 41 first degree relatives of these gene carriers. Significant
excess numbers of cancers were seen in both groups, com-
pared to expected numbers. There was a tendency for the
known gene carriers to have higher relative risk estimates.
For example, in digestive system cancers, the ratio of
observed to expected cancers was 10.1 in the known gene
carriers and 4.5 in the first degree relatives. However, this
difference was not significant.
Table II Tumour registries
Pedigree Sex Age Basis ofDx Diagnosis
Family 2
II-3 F 74 hospital rpt pancreatic carcinoma
11-5 F 64 hospital rpt pancreatic carcinoma
II-6 M 39 family rpt pancreatic cancer with jaundice
11-7 M 69 pathology bronchus carcinoma
11-9 M 63 physician pancreatic cancer
III-1 M 9 family rpt 'childhood' cancer
III-3 M 11 family rpt 'childhood' cancer
III-4 M 46 pathology squamous carcinoma of nasopharynx
III-5 F 54 pathology breast carcinoma
111-6 F 56 pathology adenocarcinoma, primary site unknown
III-15a M 49 pathology carcinoma of tongue
111-20b M 46 pathology carcinoma, larynx
Family 4
I-l M 60 hospital rpt liver carcinoma
I-3 F 70 hospital rpt carcinoma of parotid
1-4 F 68 hospital rpt stomach carcinoma
I-5 F 86 physician rpt carcinoma of oesophagus
I-6 F 77 family rpt leukaemia
1-8 M 65 pathology squamous cell carcinoma of lung
II-lb F ? family rpt pancreatic cancer
11-3b F 43 physician rpt pancreatic carcinoma
11-4 F 46 hospital rpt pancreatic carcinoma
11-5 F 75 pathology breast carcinoma
11-6 F 74 hospital rpt pancreatic carcinoma
11-7 F 71 pathology Paget of the nipple and intraductal carcinoma
11-8 M 65 pathology adenocarcinoma of prostate
II-9 M 50 physician rpt pancreatic carcinoma
1_lla M 71 hospital rpt pancreatic carcinoma
111-32 F 44 family rpt uterus cancer
III-33 F 33 pathology squamous cell carcinoma of nasopharynx
Family 106 38 pathology squamous cell carcinoma of uterine cervix
III-I M 52 hospital rpt liver carcinoma
IV-I M 58 pathology adenocarcinoma, primary site unknown, most
probably digestive tract
IV-2 F 50 pathology adenocarcinoma, probably pancreatic
IV-6a F 65 physician breast carcinoma
IV-9 M 42 physician kidney carcinoma
aCase also diagnosed with melanoma. bCase not included in analysis-no evidence of FAMMM in first degree relatives.
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Figure 2 Pedigrees of families found to have high incidence of systemic cancer. Shading indicates cases included in the systemic
cancer study. Details of extracutaneous cancer diagnoses are provided in Table II.
Discussion
Our results support the view that some FAMMM families
show evidence of an increased susceptibility to extra-
cutaneous cancers, especially to digestive tract cancers. They
also indicate that FAMMM families are heterogeneous with
regard to systemic cancer susceptibility. It remains to be seen
whether this susceptibility is an integral part of the FAMMM
syndrome or a coincidence of separate, although closely
linked, familial factors. In this connection, it is worthy of
note that no kinship has been detected among the three
cancer-prone families, nor are they known to be different, as
a group, from the six families with normal cancer frequen-
cies. All nine families are from the same region of the
Netherlands, and many members still live in the area. Fur-
thermore, each individual family is extended, including many
distant relatives. Thus, homogeneity of environmental
exposures within families is unlikely to greatly exceed
homogeneity among families. However, the possibility that
the observed heterogeneity among families may be due to
genotype/environmental interaction cannot be ruled out.
The cancers observed in the three cancer-prone families are
listed in Table II. There is no evident tendency rare cancers
or unusual histologies. For example, the pancreatic cancers
where histology was specified were adenocarcinomas. Nor is
there any general tendency for very early ages at diagnosis.
However, the clinico-pathological details of these cases were
very scanty and no conclusions can be drawn. The digestive
tract cancers are not distributed in this organ system as
would be predicted from Dutch incidence data, in which
approximately half of the digestive tract cancers are colorec-
tal and approximately 10% are pancreatic; in the studied
cases, nine of the 18 digestive tract cancers were pancreatic
and none were colorectal. This unusual pattern indicates that
the FAMMM genotype in these families increases the risk of
specific cancer types, rather than producing an increased
susceptibility to cancer at all sites.
Our results are similar to those reported by Lynch et al.
(1983). They found an excess of diagnoses of extracutaneous
cancer in 42 FAMMM gene carriers. However, in that study,
specific excesses were found in lung and breast cancer, in
addition to pancreatic cancer, in these cases. This result has
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been questioned (Greene et al., 1987) because the families
were ascertained in a setting specialising in studies of families
manifesting a diversity of cancers ('cancer family synd-
romes').
We are confident that there was no bias in favour of
families prone to systemic cancer in the Dutch FAMMM
kindred registry from which the families were selected, since
all were ascertained at a pigmented lesions clinic which was
not involved in the study of non-cutaneous cancers or
familial non-cutaneous cancer syndromes. All were ascer-
tained and studied by a dermatologist with no special interest
in hereditary cancer syndromes other than familial
melanoma.
Greene et al. (1987) avoided any ascertainment bias in a
prospective study of the occurrence ofnon-melanoma cancers
in 14 kindreds known to have the FAMMM syndrome. The
authors concluded that there was no 'striking diathesis' for
tumours other than melanoma in the families. Given the
overall negative conclusions drawn by the authors, it is sur-
prising that in the group of examined blood relatives with
dysplastic nevi (i.e. proven gene carriers of FAMMM synd-
rome), an excess of gastrointestinal tract cancers was
observed (P<O.05). This finding provides support for the
concept that other cancers, especially gastrointestinal cancers,
form an integral part of the FAMMM syndrome in at least a
subset of FAMMM families.
Virtually all of the 50 or more cancer-associated genoder-
matoses which have been described involve cancer at more
than one site (Lynch & Fusaro, 1982). Heterogeneity among
families in terms of cancer susceptibility is commonly de-
scribed in these syndromes. The same sort of phenotypic
heterogeneity characterises other cancer susceptibility synd-
romes, such as familial adenomatous polyposis where, in
certain families, a variety of extracolonic neoplasms
associated with the genotype are observed to a marked
degree, while in other families, these stigmata are seen to a
lesser extent or not at all (Jagelman, 1987). Familial
adenomatous polyposis is a well-known and long-studied
disorder, and yet the importance of extracolonic manifesta-
tions has only come to be appreciated in recent decades. The
heterogeneity among families contributed to the delay in
recognition. The situation in the FAMMM may be
analogous.
In summary, our results indicate that there exists a subset
of FAMMM families in which known gene carriers and first
degree relatives are at increased risk for the development of
systemic cancer, particularly gastointestinal cancer. Further
studies are needed to confirm this finding, to test hypothesis
about the nature of this phenomenon, to determine the size
of this systemic cancer-prone subset, and to determine wheth-
er other subsets, involving other specific sites of cancer, may
exist.
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